IDO2 and medullary thyroid gland carcinoma: In the current study, we evaluate the level of IDO2 through its immunohistochemical expression by using a large cohort of patients with MTC to unveil its correlation with clinicopathologic factors, OS/recurrence-free survival (RFS), and biochemical recurrence.